Introduction: In the pharmaceutical world, ophthalmic products (eye drops, intraocular injections, eye ointments, etc.) require exceptional care in manufacturing. The eye is a very sensitive organ, and any impurity in a product intended for ocular use can have serious consequences. One critical quality attribute that ophthalmic product manufacturers must control is particulate matter – tiny particles that shouldn’t be there. USP <<789>> is the leading standard that addresses this aspect for eye care solutions. Compliance with USP <789> isn’t just a bureaucratic box to tick; it’s fundamentally about patient safety, product quality, and regulatory trust. In this blog post, we explore what USP <789> entails, why it matters globally, the challenges companies face in meeting its requirements and how the manual microscopic method of particle testing can assist to ensure you stay compliant.

What is USP <789> and Who Requires It?

USP <789> is a compendial test method defined by the United States Pharmacopeia for measuring particulate matter in ophthalmic solutions. In essence, it sets forth how many microscopic particles of certain sizes are allowed in eye-related drug products. Regulators worldwide expect compliance with these limits. For example, the FDA in the U.S. will typically require an ophthalmic drug product’s specifications to include particulate matter limits per USP <789>. Likewise, the European Medicines Agency (EMA) and other international agencies look for similar controls via harmonized standards (the European Pharm. has a chapter analogous to USP <789>). In short, if you manufacture a sterile product meant for the eye, you need to pass the USP <789> particulate matter test to market it. This applies to common eye drops (multi-dose or single-dose vials), eye irrigation solutions, and intraocular injection preparations (for example, those anti-VEGF injections for retinal diseases). The scope even includes newer therapy types like gene therapy injections into the eye – any sterile liquid that goes in the eye must have tightly controlled particulate levels.

Under USP <789>, the acceptance criteria for particulate matter are very strict. The two key size ranges are particles ≥10 μm and ≥25 μm (i.e., 10 micrometers and 25 micrometers in diameter), and USP <789> adds a third category for particles ≥50 μm for ophthalmic products. The limits: not more than 50 particles per mL ≥10 μm, 5 per mL ≥25 μm, and 2 per mL ≥50 μm. It doesn’t matter if your product comes in a tiny 5 mL bottle or a large 50 mL bottle – the limit is calculated per milliliter. This effectively means smaller volume products carry an even smaller total allowable load of particles (e.g. a 5 mL eye drop bottle can have at most 5 × 50 = 250 particles ≥10 μm in the entire container, which is a low threshold). These limits reflect how crucial it is to minimize particulate contamination: in ocular therapies, even a small number of particles can potentially cause the patient to feel grittiness, see “floaters,” or experience eye inflammation.

Challenges in Meeting USP <789> Requirements

Ensuring that your ophthalmic product consistently meets these particulate limits can be challenging. Where do these particles come from? They are usually not ingredients, but rather contaminants introduced during manufacturing, packaging, or even formulation degradation. Common sources include environmental dust or fibers, particles shed from manufacturing equipment, fragments of container or closure materials (for example, glass flakes from vials or rubber bits from dropper tips), or precipitates of the drug/excipients if the solution is not stable. Controlling all these potential sources requires a robust quality system.

Here are few of the crucial challenges pharmaceutical companies face with USP <789> compliance:

• Limitations of Traditional Detection Methods: The primary method for subvisible particle testing in injectables and ophthalmics has long been Light Obscuration (LO). While LO automated counters are efficient, they have known blind spots. Very translucent or low-contrast particles (like protein aggregates or silicone oil droplets) might not be detected if their refractive index is similar to the solution. LO also only gives counts and sizes, not what the particles are. It might count an air bubble or a piece of fuzz as just a “particle” unless carefully validated. Because of these limitations, companies might pass LO tests while still having problematic particulate matter in their product, or conversely fail due to false counts.
• Small Batch Volumes: Ophthalmic products often come in small fill volumes (5–10 mL eye drop bottles, or 0.5 mL intravitreal injections). The USP tests typically require a certain volume to run (USP <788> for injections requires at least 25 mL sample, though USP <<789>> allows using the entire contents of several ophthalmic units to gather enough volume). Testing small volume products without wasting a lot of doses can be a challenge; you may need to pool multiple units for one test, which then has to be statistically justified.
• Complex Formulations: Some ophthalmic formulations are not simple clear solutions. You might have suspensions (solid particles intentionally present, which are exempt from USP <789>), emulsions, or viscous gels. Viscous or opaque solutions cannot be easily tested by a light obscuration instrument – the instrument may clog or give erratic readings. Also, if a product contains intrinsic suspended particles (like microcrystals in a suspension), the standard LO test isn’t applicable. USP <789> acknowledges this: certain products “for technical reasons” can’t be tested by LO and in those cases a Microscopic Particle Count Test is the method of choice. However, doing a microscopic test correctly is labor-intensive and requires special expertise (it’s manual and subject to human technique), so many labs are less experienced with it.
• Regulatory Expectations and Pressure: Failing a USP <789> test is not an option if you want to release a batch. Regulators consider particulate matter testing a critical release criterion. If your batch results are out-of-specification, you’ll likely need to initiate an investigation, possibly repeat testing, and if failure is confirmed, the batch cannot be released. Multiple failures might trigger reporting to regulators and could jeopardize product approval or supply continuity. This pressure means that the manufacturing process needs to be in control for particulates from day one. Companies must implement stringent environmental monitoring, equipment maintenance, and raw material controls to reduce particulate burden before products reach final testing. All of this adds to the operational challenges.

The Role of Manual Microscopic Particle Count (Stage 2 Testing)

Given the challenges above, the manual microscopic method for particulate testing emerges as both a necessary fallback and a powerful analytical tool. Under USP <<789>>, if an ophthalmic solution fails the initial light obscuration test (Stage 1) or if LO is deemed unsuitable, the product must pass the Microscopic Particle Count Test (Stage 2) to be considered compliant. This is where our focus lies.

What is the microscopic particle count test?

In this method, you take a measured volume of the ophthalmic solution and filter it through a very fine microporous membrane filter (typically with a pore size around 1.0 µm or less, so it traps particles ≥10 µm easily). Any particles in the liquid are captured on the filter’s surface. The filter is then carefully placed under a calibrated microscope. A trained analyst scans the entire filter systematically, looking for particles and sizing them using a microscope reticle (a special measuring grid) or an image analysis system. The counts of particles ≥10 µm, ≥25 µm, and ≥50 µm are recorded and compared against the USP <789> limits.

The manual microscopic method has numerous advantages that address LO’s limitations:

• Broader Applicability: It can be employed for solutions that LO cannot handle – for instance, highly viscous eye gels, suspensions or emulsions, and products that tend to generate bubbles. We simply filter whatever volume can pass through; even if it’s slow due to viscosity, we can get the job done. In fact, some ophthalmic products require using microscopy only (USP allows certain products to skip LO altogether if justified).
• Greater Insight: Unlike an LO counter which just gives numbers, looking at the particles under a microscope lets us see what they are. An experienced microscopist can tell, for example, a fibrous particle (which might indicate lint or filter fiber) from an irregular shard (glass or metal) or a round oily droplet. This detail is invaluable. It helps in troubleshooting failures – e.g., if you know the particles are fibers, you might investigate gowning materials or filters; if they’re glass, you might suspect the vials. The microscopic method thus provides qualitative data in addition to counts. It can even differentiate proteinaceous particles from inorganic ones by appearance to some extent. Such information enables targeted corrective actions in manufacturing.
• High Sensitivity and Accuracy: When properly performed, the microscopic count can be very accurate. The human eye (assisted by a microscope) can detect particles of different optical properties that an LO sensor might miss. For instance, transparent particles that “hide” in solution will become visible once caught on a filter. This reduces the risk of false negatives (missing particles that are actually there). Microscopy also avoids false positives from things like tiny air bubbles – an analyst can recognize and ignore an air bubble or artifact, whereas an LO machine might count it as a particle.
• Compliance Confirmation: The microscopic test is often utlized as a confirmatory test. If you get an unexpected result by LO (maybe a count slightly over the limit), performing the microscopic test can either refute or confirm the presence of particulates. However, note that per USP rules, you cannot use the microscopic test to “pass” a batch that definitively fails LO unless there is a valid scientific reason that LO was giving erroneous data. In other words, you can’t just choose the lower count method arbitrarily. But in many cases, microscopy will yield lower counts because it excludes non-particulate interference and can physically remove some particles like protein aggregates during filtering. The regulatory expectation is that you first try LO, and resort to microscopy if needed for technical reasons or to investigate discrepancies.

Our team emphasizes manual microscopic particle testing as a service because we recognize how vital it is for ophthalmic product compliance. We have invested in appropriate microscopy equipment, staff training, and controlled laboratory conditions (cleanrooms) to perform this test correctly. Through this method, we help clients identify particulate issues early, often during R&D or stability testing, so they can be resolved before regulatory submission or commercial production.

Ensuring Compliance with USP <789>: Best Practices and Benefits

Staying compliant with USP <789> yields multiple benefits for a manufacturer beyond just “avoiding trouble.” It is part of Good Manufacturing Practice (GMP) and a hallmark of a high-quality ophthalmic product. Here are some of the benefits and how to achieve them:

• Patient Safety First: Ultimately, compliance with USP <789> protects patients. By rigorously controlling particulate matter, you reduce the risk of patients experiencing adverse effects like eye irritation, pain, blurred vision, or more serious complications such as corneal scratches or eye infections caused by contaminated drops. In intraocular injections, minimizing particulates helps prevent inflammatory responses inside the eye that could impair vision. Patient safety incidents due to particulates can be devastating; compliance is a proactive way to prevent them.
• Regulatory Confidence and Market Access: A product that meets USP <789> will find favor with regulators. Global health authorities recognize USP <789> as an appropriate test for ocular products, which means a pass on USP <789> is often accepted evidence for EMA, FDA, and others that your particulate levels are under control. This opens doors to international markets. Many countries either adopt USP standards or have equivalent ones; by conforming to USP <789> you’re essentially meeting those expectations too. Additionally, showing a strong handle on particulate control during inspections or in your regulatory filings builds confidence with the regulators that you are a manufacturer who leaves no stone unturned in quality. This can streamline approvals and reduce scrutiny.
• Avoiding Costly Recalls and Production Delays: Non-compliance can halt a product launch or cause an existing product to be pulled from the market. Consider the costs: scrapping an entire batch, investigating the root cause, fixing the issue, potential regulatory penalties, and reputational damage. By investing in good particulate control and testing, you save capital in the long run. Many companies implement in-process checks (like sampling and doing particulate counts mid-production) to catch problems early. Also, including particulate monitoring in stability studies will ensure your product remains compliant throughout its shelf life, not just at release.
• Process Improvement: Monitoring what kinds of particles are found (via microscopic analysis) can drive continuous improvement. For example, if you frequently find cellulose fibers, you might switch to synthetic non-shedding wipes in the cleanroom. If you find stainless steel specks, you might perform preventative maintenance on your fluid pumps more often. USP <789> testing isn’t just a QC box to check; it’s a feedback mechanism to improve your manufacturing process. Over time, your product’s particulate profile should stay consistently low, which is a sign of a robust process.

Conclusion: Compliance with USP <789> using the manual microscopic method can seem demanding, but it is achievable with the right practices and partners. By understanding the sources of particulates and the tools available to detect them (and by leveraging expert services like ours for meticulous microscopic particle analysis), ophthalmic manufacturers can confidently produce safer, high-quality products. In doing so, they protect patients’ eyes – and their own businesses – from the risks associated with particulate matter. In the delicate realm of eye care, every particle counts, so USP <789> compliance is essential.

If you have questions about particulate matter testing for your ophthalmic product or need support to conduct a USP <789> particulate test, contact our team. With our expertise in manual microscopic particle counting and regulatory compliance, we can help ensure your eye care products meet the highest standards of quality and safety.